To review and summarize the available evidence on factors predicting prognosis of children with relapsed acute lymphoblastic leukemia (ALL) and on the currently used treatment strategies, as well as on the most promising and innovative molecular or cellular therapies.
INTRODUCTION
To date, cure is achieved in 80-85% of children with newly diagnosed acute lymphoblastic leukemia (ALL) given risk-oriented chemotherapy [1] [2] [3] . Relapse represents the main cause of treatment failure as it occurs in 15-20% of patients; 40-50% of them are rescued by intensive combination chemotherapy with or without allogeneic hematopoietic stem cell transplantation (HSCT) [4] [5] [6] [7] [8] [9] [10] . These data clearly indicate that the development of novel salvage regimens for relapsed ALL is warranted [11 && ]. ALL relapses mainly occur during treatment or within the first 2 years after therapy discontinuation, either as isolated bone marrow involvement or as bone marrow disease combined with involvement of other anatomical sites, such as the central nervous system (CNS) or the testes [8, 12] .
Current chemotherapy protocols for relapsed ALL are risk-oriented, taking into account clinical characteristics at diagnosis and relapse. In particular, site of relapse, length of first complete remission and immunophenotype of leukemia cells all affect event-free survival (EFS) and overall survival (OS) in childhood ALL. In general, isolated bone marrow relapses portend a less favorable outcome, whereas isolated CNS, isolated testicular or other extramedullary relapses carry a better prognosis [8, 13, 14] . Similarly, cure rates are lower when relapse occurs within 6 months from treatment discontinuation and in case of relapsed T-ALL [4, 8, 12, 13] .
In Europe, the Berlin-Frankfurt-Munster (BFM) classifies children with relapsed ALL into four risk groups, for example, S1, S2, S3 and S4, based on site of relapse, time from diagnosis to relapse and immune-phenotype [10] (Table 1 ). In North America, the Children's Oncology Group (COG) defines an early bone marrow relapse as that occurring less than 3 years from diagnosis and a later bone marrow relapse as that occurring more than 3 years after diagnosis. Both classifications are valuable for predicting outcome and for developing risk-oriented treatment strategies. More recently, a new prognosticator has entered the clinical arena, namely, early clearance of leukemia blasts after initial re-induction therapy (i.e., after 5 and 12-13 weeks from the beginning of treatment for relapse). Indeed, persistence of minimal residual disease (MRD), either detected by molecular techniques or by flow-cytometry, unfavorably affects prognosis [9, [15] [16] [17] . Specifically, children with MRD levels below 10 -3 or 10 -4 are at lower risk of recurrence than patients with higher levels of MRD. Similarly, molecular persistence of leukemia before transplantation may herald a high chance of disease recurrence after HSCT [18] .
In the last few years, many of the most influential cooperative groups working on childhood ALL have joined in an international effort aimed at developing risk-oriented treatments for children with relapsed ALL. This consortium, designated IntReALL, will stratify patients into standard-risk and high-risk groups ( Table 2) . Standard-risk children (60% of all relapsed patients) will receive either a chemotherapy-based treatment or allogeneic HSCT consolidation (50% of the whole population of standard-risk children), depending on MRD levels at the end of re-induction therapy. By contrast, high-risk children after being re-induced into remission will be offered an allograft, irrespectively of the availability of an HLA-matched donor ( Fig. 1 ).
Few randomized controlled trials comparing different re-induction regimens in risk-stratified children with relapsed ALL have been conducted [4,5,9,11 && ,13,15] . Thus, it remains unclear whether any re-induction combination in use today is significantly superior to any other. Children with first bone marrow relapse of ALL should be given chemotherapy protocols proved to be effective in re-inducing and consolidating a second morphological complete remission. It is advisable that children with high-risk features be treated with more aggressive chemotherapy schemes than standard-risk patients.
THE PLACE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA
Allogeneic HSCT is frequently used in pediatric patients with ALL in second complete remission
KEY POINTS
With current therapies, only 40-50% of children with relapsed ALL can be rescued by salvage therapy; thus, innovative approaches are needed.
Children with first relapse of ALL can be stratified into standard and high-risk groups, according to the length of first remission, site of relapse and leukemia cell immunophenotype.
Allogeneic HSCT is the only effective postremission treatment for children with high-risk relapsed ALL.
Measurement of minimal residual disease can help discriminate which standard-risk patients ought to be transplanted.
Novel approaches of immunotherapy based on the use of bi-specific or drug-conjugated antibodies or on the use of genetically transduced T cells appear to be particularly promising. ]. Several studies have documented that allogeneic HSCT from matched family donors (MFD) offers high chances of rescuing these patients, and the EFS of transplanted patients has been reported to be superior to that achieved in children given a second chemotherapy treatment [19, 21] . The BFM ALL-REZ-87 trial indicated that EFS was better after transplantation than after chemotherapy only in patients with high-risk or intermediate-risk ALL relapse [13] . By contrast, the COG CCG-1941 study failed to demonstrate any advantage for patients given HSCT over those treated with chemotherapy only [6] .
More than 70% of children with relapsed ALL who might benefit from an allograft lack an HLAidentical family donor. With the establishment of donor registries, many patients are able to locate a suitable unrelated donor. Results in patients transplanted for relapsed ALL suggest that unrelated donors selected through high-resolution typing of HLA loci offer minimal or possibly no disadvantage in terms of disease outcome compared with HLAidentical siblings [20, 23, 25] . Accordingly, it is reasonable to envisage that the same indications for HSCT be applied for both HLA-identical sibling donors and matched unrelated donors. A matchedpair analysis from the BFM group comparing unrelated donor HSCT with chemotherapy for children with ALL in CR2 documented that the probability of EFS was significantly higher for high-risk (44 vs. 0%) patients given the allograft [22] . Cord blood has extended the opportunity to perform HSCT to patients lacking an HLA-matched donor. Published reports have compared the outcome of umbilical cord blood transplantation (UCBT) and unrelated donor bone marrow transplant (UD-BMT) in children with hematological malignancies [26] [27] [28] . Eapen et al. ] have recently reported on 170 children with ALL in complete remission; for the 77 transplanted in CR2, the 4-year EFS was 44% and high levels of MRD before transplantation predicted an increased relapse risk.
T-cell-depleted HSCT from an HLA-haploidentical relative (haplo-HSCT) offers an immediate transplant option for patients lacking a matched donor or a suitable UCB unit [29] . The absence of T-cell-mediated graft-vs. leukemia (GvL) effect has been thought to render the recipients of T-celldepleted allografts more susceptible to leukemia relapse [29, 30] . However, fundamental studies on haplo-HSCT have shown that, in adult patients with acute myeloid leukemia transplanted in complete remission, a GvL effect could be mediated by natural killer (NK) cells when an HLA-disparate, NK-alloreactive relative was employed as donor [31] . This NK-mediated GvL effect has also been documented in children with ALL [30, 32] . A previous study analyzed outcomes of 127 children with ALL given haplo-HSCT, showing that the EFS of children with CR2 and CR3 ALL was 34 and 22%, respectively [33] . Therefore, a T-cell-depleted haplo-HSCT should be considered for patients with ALL in need of transplantation and lacking a matched donor, especially if an NK-alloreactive relative exists.
In summary, allogeneic HSCT should be offered to children with either high-risk features or poor blast clearance (e.g., high levels of MRD), as these patients (around two thirds of the overall population of relapsed children) have an otherwise dismal outcome. Whatever the type of transplant given, children should be transplanted after 2-3 courses of chemotherapy aimed at consolidating remission. Negative MRD or low MRD levels before transplantation are highly desirable to minimize the risk of leukemia recurrence after transplantation.
THE PLACE OF NEW AGENTS FOR RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA
Novel pharmacological agents, including nucleoside analogues, monoclonal antibodies, new formulations of existing chemotherapeutic agents and targeted molecules have recently become available [34] . Because many patients experiencing ALL relapse respond to the same drugs used during first-line treatment, the use of investigational agents, so far, has been restricted to patients who either experienced multiple relapses or were refractory to salvage therapies [35] .
Nucleoside analogues
Clofarabine is a second-generation purine analogue with favorable cytotoxic properties, capable to inhibit DNA synthesis and repair [36] [37] [38] [39] . In phase I/II clinical trials in heavily pretreated children with refractory/relapsed ALL, single-agent clofarabine displayed significant activity, with manageable liver toxicity and no neurotoxicity [36, 40] . More recently, clofarabine has been used in combination with agents expected to have a synergistic effect (namely, cyclophosphamide, etoposide and cytarabine).
Several trials exploring the efficacy of combining clofarabine with cyclophosphamide and etoposide in children with second bone marrow relapse or refractory ALL have been published over the last years [41] [42] [43] [44] . In these studies, clofarabine was used at a maximum dosage of 40 mg/m 2 per day for 5 consecutive days, with a 40-60% probability of reaching complete remission or complete remission without platelet recovery (CRp) [41] [42] [43] [44] . The UK pediatric cooperative group formally demonstrated that the probability of response is higher in combination regimens than for single-agent use [23] . In the same trial, clofarabine-based regimens were more effective when given in first relapse: indeed, the complete remission rate was 86% in these patients as compared to 40 and 20% when clofarabine was given for a second or third leukemia relapse, respectively [23] . In two of the combination studies, the probability of complete remission was significantly higher in patients with B-cell precursor (BCP) ALL than with T-cell ALL [41, 43] . Accordingly, in-vitro data suggest that clofarabine may be slightly more effective at killing B-lineage ALL compared with T-ALL cells [45] .
Nelarabine, a water-soluble pro-drug of Ara-G, inhibits purine nucleoside phosphorylase (PNP). Ara-G nucleotides preferentially accumulate in T cells rather than B cells. The exquisite cytotoxicity of nelarabine against T cells has prompted its evaluation in T-cell leukemias. In a phase I study in children and adults with T-ALL, nelarabine induced complete remission or partial response in 54% of patients, after one or two courses [46] . However, 50% of children and 85% of adults experienced reversible neurological toxicity. In a phase II study (POG 9673) restricted to 153 children with refractory T-ALL or T-cell non-Hodgkin's lymphoma (NHL), nelarabine at 1200 mg/m 2 for 5 consecutive days induced a 35% complete remission rate in the 79 patients without CNS involvement [47] . A higher complete remission rate was achieved in patients in first relapse (46%), compared with those in second relapse (25%) or with CNS disease (21%). Based on these promising data, the US FDA approved nelarabine for the third-line treatment of patients with T-ALL/lymphoma [48] . Recently, the COG AALL00P2 trial evaluated the safety of adding nelarabine to an intensive modified BFM86 chemotherapy regimen in children with newly diagnosed, high-risk T-ALL [49 & ]. The 5-year EFS for all patients receiving nelarabine (n ¼ 70) was 73 vs. 69% for those treated without nelarabine (n ¼ 16). This study shows that nelarabine is well tolerated and gives encouraging results in pediatric patients with T-ALL, particularly those with a slow early response, who historically have a dismal prognosis [49 & ].
Monoclonal antibodies are increasingly used in children with relapsed ALL. Epratuzumab is a humanized monoclonal antibody targeting CD22, which is highly expressed in the majority of BCP-ALL [50] . Epratuzumab has been used at 360 mg/m 2 per dose twice weekly for four doses (single-agent phase), followed by 4 weekly doses in combination with standard re-induction chemotherapy, in a pilot study enrolling 15 children with first or later bone marrow relapse of CD22 þ BCP-ALL [51] . Although the drug was substantially ineffective as single agent, it proved valuable when combined with chemotherapy, since nine of these 15 patients achieved CR, seven with negativity of MRD [51] . This agent was also evaluated in a larger phase II study in children and young adults with early relapsed CD22 þ BCP-ALL. Although well tolerated, this regimen did not improve the complete remission rate when compared with historical controls [52] . The efficacy of epratuzumab will be further investigated over the next years in a randomized controlled trial conducted by IntReALL on standard-risk patients.
Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin. A phase I trial of moxetumomab as a single drug is ongoing in childhood ALL, and preliminary data are encouraging with 24% complete and 6% partial responses [53] . Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody conjugated to the toxin calicheamicin. It has been tested, as single agent, in a phase II study in adults and children with refractory/relapsed BCP-ALL. The overall response rate was 57%; 18% of patients obtained morphological complete remis-
Blinatumomab
Blinatumomab is a murine, single-chain antibody belonging to a class of constructs, termed bi-specific T-cell engagers (BiTE) [55, 56] . Blinatumomab tethers cytotoxic T lymphocytes (CTL) to CD19-expressing B cells, irrespective of T-cell receptor specificity [55, 56] . CD19 þ lymphoma and leukemia cell lines are extremely sensitive to blinatumomab-mediated in-vitro cytotoxicity [55, 56] . Dexamethasone at concentrations between 1 and 3 Â 10 -7 mol/l did not detectably inhibit the cytotoxicity of blinatumomab-activated T cells against human B-lymphoma cells, whereas decreasing the in-vitro release of tumor necrosis factor (TNF)-a, interferon (IFN)-g, IL-6, IL-10 and IL-4 [57] . Blinatumomab was initially shown to be highly effective in 38 adults with different histological subtypes of either relapsed or refractory B-cell NHL [58] . Notably, the drug killed lymphoma cells not only within lymphoid organs, but also within the bone marrow. This observation provided the rationale for using blinatumomab in patients with refractory/resistant ALL.
An open-label, multicenter, single arm, phase II study enrolled 21 adult patients with molecularly resistant BCP-ALL and showed that the continuous intravenous infusion of blinatumomab at a dose of 15mg/m 2 per day over a 4-week cycle followed by a treatment-free period of 2 weeks induces sustained B-cell depletion within 1 day [59 & ]. T cells also rapidly declined at the beginning of treatment, likely as a result of redistribution, as suggested by a complete recovery of T-cell counts by 8-9 days after treatment initiation. T-cell expansion during the first treatment cycle, a 'first-dose effect', was accounted for by CD8 þ and CD4 þ T cells, bearing the phenotypic hallmarks of both central-memory and effector-memory T cells. Sixteen of these 21 patients (76%) became MRD negative [60] . Failure to respond was observed in four of 20 evaluable patients with MRD þ ALL and was not correlated with either baseline T-cell counts or ex-vivo T-cell activation. Serum levels of IL-10, IFN-g and IL-6 significantly increased at day þ 1, notwithstanding glucocorticoid coverage [59 & ]. More recently, 18 adult patients with relapsed/ refractory BCP-ALL were given blinatumomab in an exploratory phase II trial [61] . The drug was administered at three dose levels of 5-30mg/m 2 per day. Twelve out of 18 patients (67%) reached complete remission within the first two cycles of treatment. Of the 12 responding patients, 75% had complete hematologic recovery and all reached MRD negativity within the first two cycles. Three children with ALL in relapse after allogeneic HSCT were given blinatumomab by continuous intravenous infusion at a dose of 15 mg/m 2 per day for at least 4 weeks [62] . All patients attained molecular complete remission, defined as an MRD level less than 10 À4 [62] . A phase I multicenter study in pediatric patients with BCP-ALL, either refractory or in second or later bone marrow relapse, has shown that blinatumomab can induce morphological and molecular remissions, defined as MRD levels less than 10 -4 , in nearly 50% of children [63 & ]. Overall, blinatumomab is well tolerated and very promising in pediatric patients with relapsed BCP-ALL; in particular, it can induce a second remission and clear MRD before allografting.
Bortezomib
Bortezomib is a proteasome inhibitor that renders leukemic cells more sensitive to the apoptotic effects of chemotherapy. Bortezomib has been shown to be synergistic with dexamethasone and additive with cytarabine, doxorubicin, asparaginase and vincristine [35] . The efficacy of bortezomib in combination with cytotoxic drugs used for re-inducing remission in ALL patients has been reported in the T2005-003 phase I study by the Therapeutic Advances in Childhood Leukemia (TACL) consortium [64] . The recommended phase II dose of bortezomib, administered twice weekly for 2 weeks followed by a 1-week rest, was shown to be 1.3 mg/m 2 [65] . In the T2005-003 study, bortezomib was given at escalating doses on days 1, 4, 8, and 11, added to four-drug induction chemotherapy with vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin [64] . Overall, six of nine evaluable patients (67%) achieved complete remission, and one had bone marrow complete remission with persistent CNS leukemia. The TACL consortium recently ran a phase II expansion study in 22 patients with relapsed ALL, who failed two to three prior regimens [66 && ]. Twenty patients had BCP-ALL, whereas two patients had T-ALL. Fourteen patients achieved complete remission and two CRp, for an overall 73% response rate, meeting predefined criteria for early closure of the trial. BCP-ALL patients faired best with 16/20 (80%) complete remissionþCRp, whereas the two T-ALL patients failed to respond. This study suggests that bortezomib is active and merits further evaluation in pediatric patients with relapsed ALL, especially of the BCP phenotype.
Tyrosine kinase inhibitors
Philadelphia chromosome positive (Phþ) ALL accounts for 3-5% of pediatric ALL [67] . Tyrosine kinase inhibitors (TKIs) improve the outcome of childhood Philadelphia (Ph)-positive ALL and thus can be valuable also for relapsed patients [68] . The COG AALL0031 trial incorporated 340 mg/m 2 per day imatinib mesylate starting after completion of induction chemotherapy in 92 children and adolescents with Ph þ -ALL [68] . No imatinib-related toxicities were observed and 3-year EFS was 80%, a significant advancement compared with 35% EFS rate in historical controls during the preimatinib era. European pediatric cooperative groups have conducted the European Intergroup Study on Post-Induction Treatment of Philadelphia Positive ALL with Imatinib (EsPhALL) study in children with Ph þ -ALL. The 4-year EFS was 73 and 62% in goodrisk patients who did or did not receive imatinib, while 2-year EFS in poor-risk patients was 54%. These results indicate that the addition of imatinib mesylate to intensive BFM-type chemotherapy regimens in good-risk patients was associated with a 10% advantage in long-term EFS, which, however, was not statistically significant. The poor-risk group treated with imatinib mesylate had improved EFS as compared with historical controls [69 & ]. Dasatinib and nilotinib are second-generation TKIs shown to be superior when compared with imatinib in adults with chronic-phase chronic myeloid leukemia [70, 71] . Dasatinib is particularly attractive for Ph þ -ALL treatment, given its better CNS penetration compared with imatinib. A standard 3 þ 3 dose-escalation study from the COG aiming at defining the toxicities and determining the maximum tolerated dose of dasatinib has described efficacy in pediatric patients with imatinib-refractory Ph þ -leukemia [72] . Dasatinib may also be effective in t(17;19) BCP-ALL, a disease subset with a dismal prognosis [73] . The use of novel TKIs remains to be tested in Ph-positive, relapsed ALL through multicenter international studies.
FLT3 is a receptor tyrosine kinase playing an important role in hematopoietic stem/progenitor cell survival and proliferation. Overall, FLT3 expression has been detected in approximately 98% of pre-B ALL patients [74] . FLT3 alterations, such as internal tandem duplications (ITD) and activation loop mutations, constitutively activate the kinase activity of FLT3 and can be occasionally detected in ALL. Importantly, FLT3 is both highly expressed and phosphorylated in infant leukemias with MLL rearrangement [75] . FLT3 inhibitors display in-vitro cytotoxicity in BCP-ALL with MLL rearrangements and activated FLT3 [76, 77] . The multikinase inhibitor sorafenib reportedly inhibits both B-cell and T-cell proliferation [78] . A multicenter trial on MLL-rearranged ALL in children above the age of 1 year is ongoing.
INNOVATIVE CELL THERAPY APPROACHES
Chimeric antigen receptor (CAR)-modified T cells with specificity for CD19 hold promise for ALL immunotherapy. This therapeutic strategy is based on genetic reprogramming of T cells with artificial immune receptors that redirect them to target antigens expressed by leukemic cells [79, 80] . To date, most clinical trials have targeted CD19 on BCP-ALL [81] . Preclinical studies using adoptive transfer of CD19-CAR þ T cells into immunocompromised mice bearing CD19 þ human tumors demonstrated marked antitumor responses [82] . Based on preclinical data, clinical trials of anti-CD19 CARs have been conducted with encouraging results [80, 83, 84] . Brentjens et al. [85] treated relapsed BCP-ALL patients with autologous T cells expressing a CD19-specific, CD28/CD3z second-generation dual-signalling CAR. All patients with persistent morphological disease or MRD þ disease upon T-cell infusion benefited from rapid tumor eradication and achieved MRD-negative complete remission. The first pediatric trial with CD19-CAR þ T cells has been recently published [86 && ]. Two children with relapsed/refractory BCP-ALL received T cells transduced with an anti-CD19 CAR. Approximately 1 month after infusion, morphologic remission of leukemia with MRD less than 0.01% was achieved in both children. The clinical remission in one patient was associated with a persistent molecular remission. The other child relapsed approximately 2 months after treatment, with blast cells that no longer expressed CD19. The vigorous in-vivo expansion of CD19-CAR þ autologous T cells, persistent B-cell depletion and prominent antileukemic activity all suggest that CD19-CAR þ T cells have sustained effector functions in children with advanced ALL.
CONCLUSION
Relapsed ALL is the fourth most common childhood malignancy. Children with relapsed ALL still have an unsatisfactory outcome, despite sophisticated systems of stratification and widespread availability of allogeneic HSCT. Thus, development of novel compounds and their incorporation into current strategies for the treatment of children with relapsed ALL represents a medical priority for maximizing the chance of cure. In the next years, the scientific community will be faced with the challenge of rapidly and efficiently conducting clinical trials aimed at identifying the most effective drugs for the different subtypes of ALL. In this perspective, the creation of International Consortiums of centers devoted to the clinical testing of these compounds and the prioritization of their clinical development are more than desirable.
